Argent Biopharma Limited Director/PDMR Shareholding
15 October 2024 - 6:54PM
RNS Regulatory News
RNS Number : 2252I
Argent Biopharma Limited
15 October 2024
15
October 2024
Argent BioPharma
Ltd.
(Argent BioPharma or the Company)
PDMR
Notification
Argent BioPharma Ltd (Argent BioPharma, RGT or the
Company), advises of the following
transaction which took place on 15 October 2024 whereby, Roby Zomer
(Argent BioPharma's Managing Director & CEO) was issued
4,000,000 fully paid ordinary shares in Company at a price of
A$0.41 each following the approval of resolution 1 at a general
meeting of shareholders on 1 October 2024.
The notification below, made in
accordance with the requirements of the UK Market Abuse Regulation,
provides further detail.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
(a)
|
Name
|
Roby Zomer
|
|
2
|
Reason for the notification
|
|
(a)
|
Position
|
Managing Director and Chief Executive
Officer
|
|
(b)
|
Initial
notification/amendment
|
Initial
|
|
(c)
|
If amendment: reason
|
n/a
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
|
Full name of entity
|
Argent BioPharma Ltd
|
|
|
Legal Entity Identifier
Code
|
213800HRE3FQJ6RK4H10
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; (iv) each place where transactions have been
conducted
|
|
(a)
|
Description of the financial
instrument, type of instrument
|
Fully Paid Ordinary Shares
|
|
(b)
|
Identification Code (ISIN)
|
AU0000326647
|
|
(c)
|
Nature of transaction
|
Shares issued in accordance with the
passing of resolution 1 at a general meeting held 1 October
2024.
|
|
(d)
|
Currency
|
Price
|
Volume
|
Total
|
|
|
AUD
|
0.41
|
4,000,000
|
$1,640,000
|
|
|
Aggregated
information
|
|
|
AUD
|
0.41
|
4,000,000
|
$1,640,000
|
|
(e)
|
Date of transaction
|
15 October 2024
|
|
(f)
|
Place of transaction
|
Outside a trading venue
|
|
|
|
|
|
| |
-Ends-
Authorised for release by the Company Secretary, for further
information please contact:
About Argent BioPharma
Argent BioPharma Limited (the
Company) (ASX: RGT; LSE:
RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development
Company within the biopharmaceutical sector. The Company
focuses on multidisciplinary methods with Nanotechnology,
developing multi-target therapies for comprehensive disease
management, especially concerning the Central nervous system
(CNS) and Immunology
treatments.
Follow us through our social media
channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHGRBDGBUBDGSU
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Oct 2024 to Nov 2024
Argent Biopharma (LSE:RGT)
Historical Stock Chart
From Nov 2023 to Nov 2024
